Filtered By:
Drug: Fluoxetine

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 187 results found since Jan 2013.

Acid sphingomyelinase deactivation post-ischemia promotes brain angiogenesis and remodeling by small extracellular vesicles
AbstractAntidepressants have been reported to enhance stroke recovery independent of the presence of depressive symptoms. They have recently been proposed to exert their mood-stabilizing actions by inhibition of acid sphingomyelinase (ASM), which catalyzes the hydrolysis of sphingomyelin to ceramide. Their restorative action post-ischemia/reperfusion (I/R) still had to be defined. Mice subjected to middle cerebral artery occlusion or cerebral microvascular endothelial cells exposed to oxygen –glucose deprivation were treated with vehicle or with the chemically and pharmacologically distinct antidepressants amitriptyline,...
Source: Basic Research in Cardiology - August 29, 2022 Category: Cardiology Source Type: research

Cognitive Impairment After Stroke and Treatment with Fluoxetine: A Planned Analysis of the AFFINITY Randomised Controlled Trial
Strokes increase the risk of cognitive impairment and dementia, and the risk of post-stroke cognitive decline does not subside with time.1 Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, display neuroprotective and neuro-regenerative properties in animal models of brain ischaemia,2 raising hope that their use could lessen the detrimental effects of stroke on cognition.
Source: The American Journal of Geriatric Psychiatry - August 19, 2022 Category: Geriatrics Authors: Osvaldo P. Almeida, Graeme J. Hankey, Andrew Ford, Christopher Etherton-Beer, Leon Flicker, Maree L. Hackett, AFFINITY Trial Collaboration Tags: Letter to the Editor Source Type: research

E-194 A randomized double-blind placebo-controlled trial of prophylactic antidepressant medication for the prevention of depression post aneurysmal subarachnoid hemorrhage
ConclusionsThe initial results of this ongoing study illustrate the feasibility and challenges of mental health screening and prophylactic randomized treatment in the acute care setting for post-SAH patients. Recruitment has been a challenge in this patient population. Here we describe the trends we see in outcomes at 12-months compared to baseline. These trends suggest that despite clinical improvement there may be an increase in depression and anxiety development one-year post-aSAH.Disclosures J. Keen: None. D. Lim: None. K. Prijoles: None. H. Haughn: None. C. Galang: None. A. Duboysky: None. E. Byun: None. K. Carroll: N...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Keen, J., Lim, D., Prijoles, K., Haughn, H., Galang, C., Duboysky, A., Byun, E., Carroll, K., Kelly, C., Federico, E., Gonzalez, A., Levitt, M., Kim, L. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

MEASURING AMBULATION, MOTOR, AND BEHAVIORAL OUTCOMES WITH POST-STROKE FLUOXETINE IN TANZANIA: THE Phase II MAMBO TRIAL
We test the safety of fluoxetine post-ischemic stroke in Sub-Saharan Africa. Adults with acute ischemic stroke, seen
Source: Journal of Stroke and Cerebrovascular Diseases - March 20, 2022 Category: Neurology Authors: Emmanuel Massawe, Notburga A. Mworia, Seif Ismail, Dylan R. Rice, Andre C. Vogel, Boniface Kapina, Novath Mukyanuzi, Deus C. Buma, Jef Gluckstein, Michael Wasserman, Susan E. Fasoli, Faraja Chiwanga, Farrah J. Mateen, Kigocha Okeng'o Source Type: research

Use of antidepressants in unipolar depression in the elderly
CONCLUSIONS: Unipolar major depressive episodes in the elderly are frequent and their medicinal treatment has specific features. Knowing the specificities of antidepressant use in the elderly allows to optimize its efficiency and to limit the risk of inappropriate prescription leading to harmful adverse effects.PMID:35153054 | DOI:10.1016/j.encep.2021.11.006
Source: L Encephale - February 14, 2022 Category: Psychiatry Authors: A Pericaud C Straczek F Montastruc M Leboyer A Yrondi C Arbus Source Type: research

Measuring Ambulation, Motor, and Behavioral Outcomes with Poststroke Fluoxetine in Tanzania: The Phase II MAMBO Trial
Am J Trop Med Hyg. 2021 Dec 6:tpmd210653. doi: 10.4269/ajtmh.21-0653. Online ahead of print.ABSTRACTWe test the safety of fluoxetine postischemic stroke in sub-Saharan Africa. Adults with acute ischemic stroke, seen <14 days since new-onset motor deficits, were enrolled from November 2019 to October 2020 in a single-arm, open-label phase II trial of daily fluoxetine 20 mg for 90 days at Muhimbili National Hospital, Dar es Salaam, Tanzania. The primary outcome was safety with secondary outcomes of medication adherence and tolerability. About 34 patients were enrolled (11 were female; mean age 52.2 years, 65% < 60 year...
Source: Am J Trop Med Hyg - December 6, 2021 Category: Infectious Diseases Authors: Farrah Mateen Emmanuel Massawe Notburga Mworia Seif Ismail Dylan Rice Andre Vogel Boniface Kapina Novath Mukyanuzi Deus Buma Jef Gluckstein Michael Wasserman Susan Fasoli Faraja Chiwanga Kigocha Okeng'o Source Type: research